|

Capecitabine Tablets Clinical Trials

9 actively recruiting trials

Also known as: Biogaran Capecitabine, Capecitabine

Pipeline

Phase 2: 3Phase 3: 3Phase 1/2: 3

Top Sponsors

  • UNICANCER2
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Shanghai Yizhong Pharmaceutical Co., Ltd.1
  • Risen (Suzhou) Pharma Tech Co., Ltd.1

Indications

  • Cancer9
  • Breast Cancer6
  • Advanced Solid Tumors2
  • Metastatic Breast Cancer (MBC)1
  • Advanced Solid Tumour1

Other9 trials

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Phase 1/2
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Phase 1/2
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Phase 1/2
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Phase 2
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
Phase 2
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Phase 3
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.